Ishares Gen-immunology Hlth(IDNA)
$25.49▲1.23%
Market is closed - opens 7 PM, 29 Jul 2024
Insights
- Ishares Gen-immunology Hlth is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Ishares Gen-immunology Hlth stock suggests that it is range bound and no decision can be made based on this information
- Based on analysis of the Moving Averages technical indicator, Ishares Gen-immunology Hlth stock is in a uptrend ↗️
- Based on analysis of the Pivot Points, the current market trend for Ishares Gen-immunology Hlth stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 64.54 | Sell |
Stochastic | 89.71, 83.26 | Neutral |
Ultimate Oscillator | 59.67 | Neutral |
Stochastic Relative Strength Index | 70.05, 67.09 | Neutral |
Moving Average Convergence Divergence | 0.35, 0.25 | Buy |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 24.76 | Buy |
20 | 24.02 | Buy |
50 | 23.96 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 24.63 | Buy |
20 | 24.31 | Buy |
50 | 23.96 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 24.8 | Neutral |
20 | 23.89 | Buy |
50 | 23.83 | Buy |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 25.01 | Buy |
20 | 24.74 | Buy |
50 | 24.22 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 25.07 | Buy |
20 | 25.0 | Buy |
50 | 24.51 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 25.15 |
Resistance L2 | 25.02 |
Resistance L1 | 24.87 |
Pivot Point | 24.74 |
Support L1 | 24.59 |
Support L2 | 24.46 |
Support L3 | 24.31 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.